Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis Inc. (ORGS)
NASDAQ:AMEX Investor Relations:
orgenesis.com
Company Research
Source: GlobeNewswire
Orgenesis’ CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study Data indicate a potentially favorable safety profile with a lower incidence of Cytokine Release Syndrome Encouraged by the positive data, Harley Street Healthcare Group along with its partners intends to commit resources to set up a Global Cancer Initiative with a focus to democratize Advanced Therapies and support further clinical development sharing the risks and rewards GERMANTOWN, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced positive clinical trial results for a real-world study of CD19 CAR-T therapy, ORG-101,
Show less
Read more
Impact Snapshot
Event Time:
ORGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGS alerts
High impacting Orgenesis Inc. news events
Weekly update
A roundup of the hottest topics
ORGS
News
- Orgenesis Commences Trading on OTCQX® Best MarketGlobeNewswire
- Orgenesis Announces Reverse Stock SplitGlobeNewswire
- Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative GloballyGlobeNewswire
- Orgenesis Provides Second Quarter 2024 Business UpdateGlobeNewswire
ORGS
Sec Filings
- 11/5/24 - Form 8-K
- 11/1/24 - Form 8-K
- 10/23/24 - Form 8-K
- ORGS's page on the SEC website